SXTC vs SBFM vs CHNR

For growth investors, Sunshine Biopharma, Inc.

(SBFM) is the stronger pick with 44. 7% revenue growth year-over-year, versus -9. 7% for China SXT Pharmaceuticals, Inc. (SXTC). The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, China Natural Resources, Inc.

(CHNR) delivered a total return of -92. 8%, compared to -100. 0% for Sunshine Biopharma, Inc. (SBFM). Over 10 years, the gap is even starker: CHNR returned -93. 5% versus SBFM's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), China Natural Resources, Inc.

(CHNR) is the lower-risk stock at 1. 10β versus Sunshine Biopharma, Inc. 's 1. 33β — meaning SBFM is approximately 20% more volatile than CHNR relative to the S&P 500. On balance sheet safety, Sunshine Biopharma, Inc. (SBFM) carries a lower debt/equity ratio of 4% versus 6% for China SXT Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Sunshine Biopharma, Inc.

(SBFM) is pulling ahead at 44. 7% versus -9. 7% for China SXT Pharmaceuticals, Inc. (SXTC). On earnings-per-share growth, the picture is similar: Sunshine Biopharma, Inc. grew EPS 97. 9% year-over-year, compared to -129. 1% for China SXT Pharmaceuticals, Inc.. Over a 3-year CAGR, SBFM leads at 434. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

China Natural Resources, Inc.

(CHNR) is the more profitable company, earning 0. 0% net margin versus -189. 8% for China SXT Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CHNR leads at 0. 0% versus -154. 0% for SXTC. At the gross margin level — before operating expenses — SBFM leads at 30. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, China Natural Resources, Inc.

(CHNR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 10)). Both have compounded well over 10 years (CHNR: -93. 5%, SBFM: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SXTC (Healthcare) and SBFM (Healthcare) and CHNR (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SXTC is a small-cap quality compounder stock; SBFM is a small-cap high-growth stock; CHNR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.